DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for sacral ...
Dublin-based Medtronic plc has filed a PMA supplement with the U.S. FDA for its next-generation, implantable sacral neuromodulation (SNM) device, Interstim Micro, and for its Interstim Surescan MRI ...
Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
In 2020, hot on the heels of Axonics Modulation Technologies’ FDA approval for a rechargeable neuromodulation implant to treat urinary and bowel dysfunction, Medtronic scored a regulatory win of its ...
Medtronic’s MDT neuromodulation business advanced recently with the company receiving FDA’s expanded MRI labeling approval for its InterStim line of sacral neuromodulation (SNM) systems. The updated ...
The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...
DUBLIN, Feb. 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results